Signaturefd LLC Has $306,000 Stake in Royalty Pharma plc (NASDAQ:RPRX)

Signaturefd LLC lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 85.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,886 shares of the biopharmaceutical company’s stock after buying an additional 5,007 shares during the quarter. Signaturefd LLC’s holdings in Royalty Pharma were worth $306,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. CWM LLC grew its holdings in Royalty Pharma by 75.9% during the third quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 2,064 shares during the period. Handelsbanken Fonder AB grew its holdings in Royalty Pharma by 17.7% during the third quarter. Handelsbanken Fonder AB now owns 931,636 shares of the biopharmaceutical company’s stock valued at $25,285,000 after purchasing an additional 140,300 shares during the period. Linden Thomas Advisory Services LLC acquired a new position in Royalty Pharma during the third quarter valued at approximately $782,000. Ridgewood Investments LLC grew its holdings in Royalty Pharma by 19.8% during the third quarter. Ridgewood Investments LLC now owns 25,787 shares of the biopharmaceutical company’s stock valued at $700,000 after purchasing an additional 4,267 shares during the period. Finally, Xponance Inc. grew its holdings in Royalty Pharma by 38.8% during the third quarter. Xponance Inc. now owns 18,218 shares of the biopharmaceutical company’s stock valued at $494,000 after purchasing an additional 5,090 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. The Goldman Sachs Group cut their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. Finally, Bank of America cut their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, April 12th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $46.75.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $28.00 on Friday. The company has a quick ratio of 7.90, a current ratio of 7.90 and a debt-to-equity ratio of 0.61. The company’s fifty day simple moving average is $29.61 and its 200-day simple moving average is $28.55. Royalty Pharma plc has a 12 month low of $25.92 and a 12 month high of $35.76. The firm has a market cap of $16.73 billion, a PE ratio of 14.81 and a beta of 0.45.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The firm had revenue of $736.00 million for the quarter, compared to analyst estimates of $702.90 million. Equities research analysts expect that Royalty Pharma plc will post 3.95 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 17th will be issued a $0.21 dividend. The ex-dividend date is Thursday, May 16th. This represents a $0.84 annualized dividend and a dividend yield of 3.00%. Royalty Pharma’s dividend payout ratio is currently 44.44%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.